• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1995.04a
• /
• pp.127-127
• /
• 1995

The present study was conducted to examine the effect of recombinant bovine somatotropin(${\gamma}$ bST), which was administered to cow to promote milk production, on bST levels in milk. Fourteen cows were divided into two groups: 1) control cows received neither y bST nor vehicle, 2) treated cows were administered twice at two-week interval with 500mg ${\gamma}$ bST each cow by subcutaneous injection. Milk samples were taken on day 0 (prior to injection), day 7 (7 days after 1st injection), day 21 (7 days after 2nd injection) and day 35 (21 days after 2nd injection).

• Journal of Environmental Science International
• /
• v.17 no.2
• /
• pp.249-255
• /
• 2008

The experiment was conducted to determine effect of the mixed herbal medicine for the substitution of antibiotics on the performance of laying hens. Day old hyline 1,500 layer chicks were randomly assigned to 4 treatments. Control were 600 chicks and there were three treatments of each 300 chicks. The 4 treatments were as follows: the mixed herbal medicine 0.1%(T-1), 0.3%(T-2) and 0.5%(T-3) after removed antibiotics on commercial feed and commercial feed( control) from 5th week to 13th week, each treatment was replicated 3 times and from 14th week to 18th week. Each 100 hens of the mixed herbal medicine 0.1%(CT-1), 0.3%(CT-2) and 0.5%(CT-3) were moved to cage. Body weight were measured on 4th, 8th, 13th week and feed intake, mortality were measured on every weeks. Body weight at fourth week, all treatments tended to be higher than control and T-3 statistically was highest(p<0.01). On 8th week, also treatments statistically high and T-1 was highest(p<0.01). But 12th week, there was not significantly different among treatments. Therefore it will be possible that the mixed herbal medicine substitute for antibiotics after vaccination. Mortality was not different between treatment and control overall rearing period. Early laying period($19{\sim}41wk$), T-2 showed highest feed intake(107.1g) among treatments, later laying period($42{\sim}77wk$), T-1 showed highest feed intake(134.3g) and was not any different among each treatments.

• Korean Journal of Biological Psychiatry
• /
• v.3 no.2
• /
• pp.262-268
• /
• 1996

It has been known that clozapine is more selective mesolimbic dopamin $D_2$ receptor antagonist and related to 5-HT receptor. In this study, we wxamined the plasma homovanillic acid(HVA), serotonin(5-HT), and 5-hydroxyindoleacetic acid(5-HIM) levels in refractory schizophrenics during clozapine treatment. And we assessed the effects of clozapine on these plasma monoamine metabolites and their association with psychopathology and treatment response. Eight refractory schizophrenic patients(DSM-IV) have entered the study for 3 months during clozapine treatment. Patients were admitted to the inpatient sevice and withdrawn from all neuroleptics for 7-14 days but exceptionally occasional doses of lorazepam was given if needed for behavioral control. The dose of clozapine was titrated as tolerated to 800mg/day. The plasma HVA. 5-HIM and 5-HT levels were measured before treatment and following 2nd week, 4th week, 8th week, and 12th during treatment. Psychopathology was assessed with Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Synrome Scale(PANSS) before and during clozapine treatment. During clozapine treatment, no statistically significant changes were found in plasma HVA, 5-HIM, 5-HT levels, and HVA/5-HIM ratio between baseline and following 2nd week, 4th week, 8th week, 12th week. However, the change in plasma 5-HIAA/5-HT ratio from baseline to 4th week was statistically significant. Generally, changes of plasma HVA, 5-HIAA, 5-HT levels and HVA/5-HIAA ratio were not associated with psychopathology but 5-HIAA was associated with in positive symptoms and general psychopathology of PANSS. These results suggest that clozapine has been found to have relatively weak dopaminergic blokade and stronger serotonergic antagonism.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 2006.11a
• /
• pp.139-145
• /
• 2006

Kaneka Corporation (Kaneka) has been manufacturing CoQ10 under GMP regulation since 1977. Kaneka has a sophisticated quality control system and has been supplying high quality CoQ10 materials to the worldwide customers (Kaneka CoQ10) for about 30 years. Kaneka CoQ10 is characterized by a lot of safety data, which are derived from clinical trials with healthy volunteers (single-dose and 4-week multi-dose safety studies), animal studies (13-week sub-chronic study in dogs and 52-week chronic study in rats), three types of mutagenicity test, six type of skin irritation test (for cosmetics), and others. The risk assessment of CoQ10 was performed by Council for Responsible Nutrition (USA). They reviewed many of available clinical data including clinical trials using Kaneka Q10, and concluded that the upper level for supplements (ULS) of CoQ10 is 1,200 mg/day (Hathcock and Shao. 2006, Regulatory Toxicology and Pharmacology, 45, 282 - 288).

• Toxicological Research
• /
• v.31 no.4
• /
• pp.371-392
• /
• 2015

TS-DP2 is a recombinant human granulocyte colony stimulating factor (rhG-CSF) manufactured by TS Corporation. We conducted a four-week study of TS-DP2 (test article) in repeated intravenous doses in male and female Sprague-Dawley (SD) rats. Lenograstim was used as a reference article and was administered intravenously at a dose of $1000{\mu}g/kg/day$. Rats received TS-DP2 intravenously at doses of 250, 500, and $1000{\mu}g/kg/day$ once daily for 4 weeks, and evaluated following a 2-week recovery period. Edema in the hind limbs and loss of mean body weight and body weight gain were observed in both the highest dose group of TS-DP2 and the lenograstim group in male rats. Fibro-osseous lesions were observed in the lenograstim group in both sexes, and at all groups of TS-DP2 in males, and at doses of TS-DP2 $500{\mu}g/kg/day$ and higher in females. The lesion was considered a toxicological change. Therefore, bone is the primary toxicological target of TS-DP2. The lowest observed adverse effect level (LOAEL) in males was $250{\mu}g/kg/day$, and no observed adverse effect level (NOAEL) in females was $250{\mu}g/kg/day$ in this study. In the toxicokinetic study, the serum concentrations of G-CSF were maintained until 8 hr after administration. The systemic exposures ($AUC_{0-24h}$ and $C_0$) were not markedly different between male and female rats, between the administration periods, or between TS-DP2 and lenograstim. In conclusion, TS-DP2 shows toxicological similarity to lenograstim over 4-weeks of repeated doses in rats.

• 한국약용작물학회:학술대회논문집
• /
• 2006.11a
• /
• pp.139-145
• /
• 2006

Kaneka Corporation (Kaneka) has been manufacturing CoQ10 under GMP regulation since 1977. Kaneka has a sophisticated quality control system and has been supplying high quality CoQ10 materials to the worldwide customers (Kaneka CoQ10) for about 30 years. Kaneka CoQ10 is characterized by a lot of safety data, which are derived from clinical trials with healthy volunteers (single-dose and 4-week multi-dose safety studies), animal studies (13-week sub-chronic study in dogs and 52-week chronic study in rats), three types of mutagenicity test, six type of skin irritation test (for cosmetics), and others. The risk assessment of CoQ10 was performed by Council for Responsible Nutrition (USA). They reviewed many of available clinical data including clinical trials using Kaneka Q10, and concluded that the upper level for supplements (ULS) of CoQ10 is 1,200mg/day (Hathcock and Shao. 2006, Regulatory Toxicology and Pharmacology, $\underline{45}$, 282 - 288).

• Communications for Statistical Applications and Methods
• /
• v.18 no.2
• /
• pp.237-244
• /
• 2011

In call forecasting literature, both the seasonal autoregressive integrated moving average(ARIMA) type models and seasonal linear models have been popularly suggested as competing models. However, their parallel comparison for the forecasting accuracy was not strictly investigated before. This study evaluates the accuracy of both the seasonal linear models and the seasonal ARIMA-type models when predicting intra-day call arrival rates using both real and simulated data. The seasonal linear models outperform the seasonal ARIMA-type models in both one-day-ahead and one-week-ahead call forecasting in our empirical study.

• Journal of Physiology & Pathology in Korean Medicine
• /
• v.26 no.2
• /
• pp.189-198
• /
• 2012

Our former study indicated efficacy of apoptotic cell death on animal study by using Egg white combined Chalcanthite (EC). Clinically, bamboo salt is using because of safety. Hence we investigated a toxicity study for determining safety by adding bamboo salt in former materiel. We had two studies: toxicity of EC and of Bamboo salt with egg white combined Chalcanthite (BC). Both were studied in 1-week single and 5-week repeated oral dose toxicity tests on male Imprinting Control Region mice. In EC, doses used in 1 week single oral dose toxicity tests were 0, 0.05, 0.5, 5 and 50 mg/kg/day and 0, 0.01, 0.05, 0.25 and 0.5 mg/kg/day. In BC, doses used by 0, 0.08, 8.3, 83.3 and 166.6 mg/kg/day in single oral dose toxicity and 0, 4.2, 8.3, 41.7 and 83.3 mg/kg/day in repeated oral dose toxicity tests. Their blood and urine were assayed and organ morphology were examined. Mann-Whitney U test and ANOVA tests were used by analysing methods. First, significant increased left renal weight in all groups of EC and BC. Second, increased ALT score was found in EC-S2 and increased relative liver weight was found in EC-S3. In addition, increased relative weight and urine bilirubin and urobilinogen were found in EC-R2 and EC-R3. There was no significant toxic change in BC. The Mixture of EC had a possibility of hepatotoxicity in the short and long term. Processed BC appears to be safe and non-toxic in these studies and a no-observed adverse effect level (NOAEL) was established at 83.3 mg/kg/day in mice. Relatively, The BC were safer than The EC.

• Journal of Ginseng Research
• /
• v.31 no.1
• /
• pp.34-43
• /
• 2007

Background: Previous research has suggested that single doses of a standardised Panax ginseng extract can decrease fasted blood-glucose levels and modulate cognitive performance in healthy young volunteers. The latter has generally been seen in terms of improved secondary memory performance. However, both the cognitive effects of chronic administration of ginseng and the potential modulation of working memory have received comparatively little research attention. Aims: The current double-blind, placebo-controlled, balanced cross-over study investigated the effects of 8-weeks administration of Korean ginseng extract (200 mg) on cognitive performance, gluco-regulatory parameters and ratings of subjective mood and 'quality of life'. Methods: 'Eighteen healthy young participants were assessed pre-dose and 3 hours post-dose on the mornings of Day 1, Day 29 and Day 57 of 8 week treatment regimens of both placebo and ginseng. A four-week placebo wash-out separated the treatment phases. Each assessment included the Cognitive Drug Research battery, computerised working memory tasks, and Bond-Lader mood scales. The WHO Quality of Life scale (WHOQOL-BREF) was completed once per visit. Gluco-regulatory parameters were assessed with assays of blood glucose, insulin and HbA1c. Results: Data from the 16 participants that completed the study showed that there were no significant, acute treatment related differences on Day 1 of treatment, or in gluco-regulatory parameters throughout the study. However, time related performance improvements were evident following chronic administration of ginseng on the '3-Back' and 'Corsi-block' computerised working memory tasks. Ginseng was also associated with an improved score on the 'social relations' subscale of the WHOQOL-100, and a significant shift on the 'calm' factor of the Bond-Lader mood scales (from calm/relaxed towards excited/tense). Conclusion: The results of the current study suggest that Korean ginseng extract can modulate working memory performance and subjective ratings of 'quality of life' and mood. Replication with a larger sample size may further elucidate the actions of this product.

• Journal of International Academy of Physical Therapy Research
• /
• v.7 no.2
• /
• pp.1056-1065
• /
• 2016

The purpose of this study was to determine the effects of music therapy and ball exercise on women experiencing menstrual discomforts, thereby identifying the validity of these methods as interventions against menstrual discomforts, with a particular goal of presenting basic data for clinical use. Twenty university students in their 20s were assigned to two therapy groups in a sequence via simple random sampling; ten subjects attended a ball exercise combined with music therapy group and the other ten subjects attended a music therapy group. Ball exercises were conducted 3 times per week for a total of 12 times, starting from 3 weeks before the expected first day of the menstrual period and ending on the last day of the menstrual period. Similarly, the subjects participated in music therapy by listening to music for 35 minutes per session and 3 sessions per week, starting from 3 weeks before the expected first day of the menstrual period and ending on the last day of the menstrual period. Five out of six categories of menstrual discomforts were significantly decreased in both music therapy and ball exercise, the exception being changes in the autonomic nervous system, while those in the music therapy group showed a significant difference only in the category of behavioral changes. The results of the present study demonstrate that the ball exercise combined with music therapy more effective in improving menstrual discomforts than the music therapy group.